Status: Study Complete
A Phase 1 Trial entitled CANON (CAVATAK in NON– muscle invasive bladder cancer) has been completed at the Surrey Cancer Research Institute, United Kingdom. This trial investigated the intravesicular use of CAVATAK® for treatment of non-muscle invasive bladder cancer (NMIBC) .
The first stage of the CANON study evaluated CAVATAK delivered as a monotherapy via a catheter directly into the bladder. The second stage of the study examined CAVATAK given in conjunction with mitomycin C by the same route of administration, with a goal of establishing a recommended Phase 2 dosing regimen for the combination therapy.
Investigators also examined the pharmacodynamics of CAVATAK and documented any evidence of anti-tumour activity.
For further information about this trial, please visit the Clinical Trial website at ClinicalTrials.gov Identifier: NCT02316171
The trial was completed in late 2016 with evidence of anti-cancer activity and tumour targeting demonstrated. Click here for the latest news on the CANON study